SB218078 inhibits angiogenesis and epithelial-mesenchymal transition in breast cancer
SB218078 emerges as a promising dual-action therapeutic candidate for breast cancer, simultaneously blocking angiogenesis and EMT through the Chk1-ZEB1 axis. Its specificity for ZEB1, distinct from other EMT regulators, offers a novel strategy to overcome the limitations of traditional VEGFR2 inhibitors, warranting further preclinical development.
Authors
- Jin Yu (ORCID: https://orcid.org/0000-0001-8224-1374)
- Xin Tang (ORCID: https://orcid.org/0000-0002-0372-478X)
- Benhua Li
- Qianxue Wu
- Xiang Zhang (ORCID: https://orcid.org/0000-0003-1003-9892)
- Jun Yang (ORCID: https://orcid.org/0000-0003-1613-337X)
- Jiawei Xu (ORCID: https://orcid.org/0009-0008-5642-6373)
Institutions
- Second Hospital of Yichang (CN)
- The Affiliated Yongchuan Hospital of Chongqing Medical University (CN)
- Chongqing Jiulongpo People's Hospital (CN)
- First People's Hospital of Chongqing (CN)
- Chongqing Medical University (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-03-14
- DOI
- https://doi.org/10.3389/fphar.2025.1552707
- Citations
- 1
- Primary Topic
- Angiogenesis and VEGF in Cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.81